Treatment of pediatric Burkitt lymphoma in Turkey.
This study aimed to assess the demographic data and treatment results of children who were diagnosed with Burkitt lymphoma and treated according to the Berlin-Frankfurt-Münster-95 (BFM) protocol in a single institution. A total of 48 patients (37 boys, 77%) with a median age of 8 years (range 2 to 16 years) at diagnosis, were evaluated. Primary tumor sites were abdomen (70.8%), head and neck (22.9%), peripheral lymph node (2%), bone (2%), and testis (2%). The 5-year overall survival (OS) and event-free survival (EFS) were 78.1±4% and 76.6±6%, respectively. In univariate analysis, hemoglobin level less than 10 g/dL, cerebrospinal fluid (CSF) positivity and dialysis requirement at diagnosis were found to be important reverse predictor factors for EFS (P; 0.001, 0.001, 0.004, respectively). In multivariate analysis, hemoglobin level less than 10 g/dL and dialysis at diagnosis were found to be important reverse predictor factors for EFS (P; 0.0001). The EFS of our patients was lower than the values achieved with BFM-95 protocol in other centers. This study provides evidence that low hemoglobin level, CSF positivity and dialysis at diagnosis were important predictor factors for EFS in children with Burkitt lymphoma.
Celkan
Tiraje Tülin
TT
Pediatric Hematology-Oncology, Cerrahpasa Faculty of Medicine, Marmara University Faculty of Medicine, Istanbul. tirajecelkan@yahoo.com
Bariş
Safa
S
Ozdemir
Nihal
N
Ozkan
Alp
A
Apak
Hilmi
H
Doğru
Omer
O
Karaman
Serap
S
Canbolat
Aylin
A
Ozdil
Mine
M
Aki
Hilal
H
Adaletli
Ibrahim
I
Kurugoglu
Sebuh
S
Hallac
Mehmet
M
Yildiz
Inci
I
D000008:Abdominal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D001706:Biopsy; D001859:Bone Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D016019:Survival Analysis; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D014421:Turkey / Q000453:epidemiology; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D014750:Vincristine; D001215:Asparaginase; D011241:Prednisone; D003630:Daunorubicin